Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil versus rivastigmine versus placebo for ECT-related cognitive deficits
IRCT20171229038124N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Nov 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in electroconvulsive therapy-associated cognitive impairment (ECT-ICI) comparing Rivastigmine, Donepezil and Placebo (3 arms). Primary endpoint: Cognitive function. Started Nov 2017; status: completed.
02
Drugs
rivastigminedonepezil
03
Conditions
electroconvulsive therapy-associated cognitive impairment (ECT-ICI)
Beyond the preview
Go deeper on IRCT20171229038124N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171229038124N1.